CAJ | 학술논문

目的观察MRC UKALL Ⅻ/ECOG E2993方案诱导缓解中国成年人急性淋巴细胞白血病(ALL)的疗效和患者不良反应.方法采用MRC UKALL Ⅻ/ECOG E2993诱导缓解方案治疗初治的11例ALL患者.结果 11例患者均达到完全缓解(CR),CR率100%,其中8例患者在第一阶段治疗结束后即达CR.在可随访的8例患者中,5例持续CR,最长生存期30个月,3例复发.该方案骨髓抑制较为强烈,对肝功能有一定影响,主要表现为丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高,经对症治疗后肝功能多可恢复正常.11例患者中无一例因治疗相关死亡.结论 MRC uKALL Ⅻ/ECOG E2993方案适用于中国成年人ALL的诱导化疗.
목적 관찰MRC UKALL Ⅻ/ECOG E2993방안유도완해중국성년인급성림파세포백혈병(ALL)적료효화환자불량반응.방법 채용MRC UKALL Ⅻ/ECOG E2993유도완해방안치료초치적11례ALL환자.결과 11례환자균체도완전완해(CR),CR솔100%,기중8례환자재제일계단치료결속후즉체CR.재가수방적8례환자중,5례지속CR,최장생존기30개월,3례복발.해방안골수억제교위강렬,대간공능유일정영향,주요표현위병안산안기전이매화천동안산안기전이매승고,경대증치료후간공능다가회복정상.11례환자중무일례인치료상관사망.결론 MRC uKALL Ⅻ/ECOG E2993방안괄용우중국성년인ALL적유도화료.
Objective To observe the efficacy and adverse effects of MRC UKALL Ⅻ/ECOG E2993 regimen in inducing remission of Chinese adults with acute iymphoblastic leukemia(ALL). Methods 11 cases of previously untreated ALL patients were treated with MRC UKALL Ⅻ/ECOG E2993 regimen, then observe the efficacy and adverse effects. Results All of the 11 patients achieved complete rcmission(CR), the CR rate was 100 %. Among the 11 patients,8 patients achieved CR after the first course of chemotherapy. In the 8 patients which could be followed up, 5 patients achieved durative CR, among that the longest survival time was 30 months, and 3 patients had relapses. This regimen has a severe myelosuppression. There was an effect on liver function, mostly in the increase of glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase.After the symptomatic treatment, liver function could return to normal. No treatment-related deaths occurred. Conclusion MRC UKALL Ⅻ/ECOG E2993 regimen can be used as inducing remission therapy for Chinese adults with acute lymphoblastic leukemia.